Product Pipeline

Developing drugs for drug-resistant, life threatening infections.

Product Candidates

The next generation of anti-infectives.

We intend to develop and commercialize novel therapeutic agents to treat life-threatening infections, including those caused by drug-resistant pathogens. The increasing prevalence of antibiotic resistance among bacterial pathogens has been widely recognized as an urgent public health threat by the CDC, the WHO and the Infectious Disease Society of America.

Our most advanced product candidate is CF-301, a lysin for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant ("MRSA") or methicillin-susceptible Staph aureus. We also continue to explore variants of CF-301 to expand our portfolio of lysins targeting biofilm-associated Staph aureus infections. We have engineered a novel mutant variant, CF-296, which has properties we believe may make it a promising potential treatment for invasive Staph aureus infections, including prosthetic joint infections. Additionally, we are focused on researching lysin therapeutics for the treatment of infections caused by gram-negative pathogens, including multi-drug resistant strains. We also continue to progress CF-404, which is an aerosolized formulation of three human mAbs for the potential treatment of life-threatening human influenza which targets all seasonal and most pandemic strains of influenza.

*CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.

Product Candidates

Market Need

Drug resistance is a global crisis

2 Million

Illnesses Diagnosed in the U.S.


Deaths, Worldwide


A bigger killer than HIV/AIDS, Parkinson's Disease, emphysema and homicide, in the U.S.


Likelihood of death among individuals with MRSA Versus those infected with MSSA


Projected Annual Worldwide Statistics in 2050

10 Million

Deaths Annually

$100 Trillion

Costs By 2050


Our Technology

Our platform enables the production of lysin banks specific for any particular bacterial pathogen

Learn More »

Contrafect Corporation

We are focused on developing protein and antibody therapeutics for life-threatening infections.

Learn More »